NCT04284033 is a NA clinical trial of Extended Wear Infusion Set in Type 1 Diabetes, sponsored by Stanford University.

Who is sponsoring NCT04284033?

NCT04284033 is sponsored by Stanford University.

What drugs are being tested in NCT04284033?

Interventions in NCT04284033: Extended Wear Infusion Set, Standard Infusion Set.

What condition does NCT04284033 study?

NCT04284033 studies Type 1 Diabetes.

Is NCT04284033 still recruiting?

NCT04284033 is currently withdrawn. Last updated 2 September 2021.

Last reviewed 2021-09-02 · How we verify

NCT04284033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy

Withdrawn NA Last updated 2 September 2021

What this trial tests

NA trial testing Extended Wear Infusion Set in Type 1 Diabetes. Withdrawn.

Timeline

14 February 2017

Primary endpoint
10 November 2017

20 April 2018

Quick facts

Lead sponsor	Stanford University
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Start date	14 February 2017
Primary completion	10 November 2017
Estimated completion	20 April 2018
Sites	1 location across United States

Drugs / interventions tested

Extended Wear Infusion Set
Standard Infusion Set

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

Stanford University

Who can join

18 and older, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized trial to determine if an extended wear infusion set can be worn for up to 7 days with a hybrid closed-loop system in adult with Type 1 Diabetes

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Stanford University trials

Trials by the same sponsor.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04284033 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stanford University
Last refreshed: 2 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04284033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing